COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
IpiNovyx Bio develops a platform for selective, reversible small-molecule immunoproteasome inhibitors to modulate immune cell types for autoimmune and inflammatory diseases, advancing preclinical candidates toward IND-enabling studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
